As the special income of Remnicivir, a Corona 19 treatment, is decided, attention is also focused on which patients can be prescribed.

According to the Ministry of Food and Drug Safety and the medical community, not all Corona19 patients can receive Remedyvir.

Among Corona19 patients, it can be used only for severely inpatient patients whose oxygen saturation falls below a certain level or requires supplemental oxygen treatment.

Remedyvir may also be prescribed for severely ill patients who require non-invasive or invasive mechanical ventilation or ecmo (ECMO).

If severe, it can be given to pediatric patients as well as adults.

The total administration period should be within 10 days.

However, the majority of Korean Corona19 patients are mild, so it is unlikely that there will be many patients who need real remedyvir.

A mild patient staying in a life treatment center often improves naturally after taking sufficient rest.

As of today (3rd), at 0:00 Corona 19 out of 177,000 confirmed patients in Korea, 850 were in quarantine.

Of these, only 8 patients (severe 1 and 7 in severe) have severe or more severe stages of oxygen therapy.

In Korea, patients who can breathe on their own, but have poor oxygen saturation due to pneumonia, etc., are classified as'severe' in patients with corona19 who receive secondary oxygen therapy.

'Severe' patients are mechanically breathing or use an artificial cardiopulmonary device, ECMO.

The medical community immediately agrees that there are not many serious patients eligible for remedyvir, but recommends that medicines be stored in the event of a major outbreak.

Prof. Bae Ji-hwan, professor of infectious medicine at Seoul National University, said, "If we assume that 60% of the population is affected by corona19, and that the collective immunity is spreading, the epidemic will stop. "I don't know how much the epidemic will grow in the future, but I advise you to stock up now so that there will be no shortage of medicines at that time," he advised.

The Ministry of Food and Drug Affairs approved the special income of Gilead Science's'Lemdesibir' today.

The Ministry of Food and Drug Affairs is planning to cooperate with Gilead Science Korea, the Governor of Disease Control and Gilead Sciences, so that Remdesivir can be imported into Korea as soon as possible. 

(Photo = Yonhap News)